Patents by Inventor Elazer R. Edelman

Elazer R. Edelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200368017
    Abstract: A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
    Type: Application
    Filed: November 16, 2018
    Publication date: November 26, 2020
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Sophie-Charlotte Hofferberth, Pedro J. del Nido, Elazer R. Edelman, Peter E. Hammer, Christopher Payne
  • Publication number: 20200359911
    Abstract: A method, including: obtaining, by a processor, imaging data from a vessel; detecting, using the processor, an inner wall of the vessel based on the imaging data; identifying, using the processor, a plurality of visible edge portions of an outer wall of the vessel based on the imaging data; fitting, using the processor, a continuous surface model to the plurality of identified visible edge portions of the outer wall; and detecting, using the processor, the outer wall of the vessel based on fitting the continuous surface model to the plurality of identified visible edge portions of the outer wall such that the imaging data has defined therein a wall area between the inner wall and the outer wall of the vessel.
    Type: Application
    Filed: May 17, 2019
    Publication date: November 19, 2020
    Inventors: Max Louis Olender, Lambros Anthanasiou, Elazer R. Edelman
  • Publication number: 20200360135
    Abstract: A replacement heart valve device is disclosed. In some embodiments, the device includes a frame coupled to one or more leaflets that are moveable between open and closed configurations. In some embodiments, the frame comprises at least two frame sections that join at a pair of commissural posts. In some embodiments, the device may be geometrically accommodating to adapt to different vasculature shapes and sizes and/or to be able to change size while implanted within a growing patient.
    Type: Application
    Filed: June 2, 2020
    Publication date: November 19, 2020
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Sophie-Charlotte Hofferberth, Pedro J. del Nido, Elazer R. Edelman, Peter E. Hammer, Christopher Payne
  • Patent number: 10780195
    Abstract: Methods, compositions, kits, and drug delivery devices are provided for treating, adhering, or sealing biological tissues. The methods include combining a first solution that includes an oligomer/polymer component and a second solution that includes a dendrimer component, and at least one of the oligomer/polymer component and dendrimer component includes at least one substituent that is capable of photoreversible dimerization. The reversible dimerization of the substituent may allow for the reversible dimerization and/or polymerization of one or more components. The substituent that is capable of photoreversible dimerization may be active by the application of light, such as UV light.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: September 22, 2020
    Assignee: Massachusetts Instiitute of Technology
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes, Yi Zhang
  • Patent number: 10736914
    Abstract: Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 11, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes
  • Publication number: 20200146561
    Abstract: The systems and methods described herein determine metrics of cardiac or vascular performance, such as cardiac output, and can use the metrics to determine appropriate levels of mechanical circulatory support to be provided to the patient. The systems and methods described determine cardiac performance by determining aortic pressure measurements (or other physiologic measurements) within a single heartbeat or across multiple heartbeats and using such measurements in conjunction with flow estimations or flow measurements made during the single heartbeat or multiple heartbeats to determine the cardiac performance, including determining the cardiac output. By utilizing a mechanical circulatory support system placed within the vasculature, the need to place a separate measurement device within a patient is reduced or eliminated. The system and methods described herein may characterize cardiac performance without altering the operation of the heart pump (e.g., without increasing or decreasing pump speed).
    Type: Application
    Filed: June 19, 2019
    Publication date: May 14, 2020
    Inventors: Qing Tan, Ahmad El Katerji, Noam Josephy, Elazer R. Edelman, Brian Yale Chang, Steven Keller, Sonya Sanat Bhavsar
  • Publication number: 20200086022
    Abstract: The systems and methods described herein determine metrics of cardiac performance via a mechanical circulatory support device and use the cardiac performance to calibrate, control and deliver mechanical circulatory support for the heart. The systems include a controller configured to operate the device, receive inputs indicative of device operating conditions and hemodynamic parameters, and determine vascular performance, including vascular resistance and compliance, and native cardiac output. The systems and methods operate by using the mechanical circulatory support device (e.g., a heart pump) to introduce controlled perturbations of the vascular system and, in response, determine heart parameters such as stroke volume, vascular resistance and compliance, left ventricular end diastolic pressure, and ultimately determine native cardiac output.
    Type: Application
    Filed: June 19, 2019
    Publication date: March 19, 2020
    Inventors: Ahmad El Katerji, Qing Tan, Christian Moyer, Alexander Ship, Sonya Sanat Bhavsar, Noam Josephy, Elazer R. Edelman, Brian Yale Chang, Steven Keller
  • Publication number: 20200038208
    Abstract: A method and an apparatus to create a more favorable flow regime in a lumen. An artificial shape in the lumen is created to at least one of eliminate flow disturbances and enhance aspects of fluid flow through a treatment site.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventors: Yoram RICHTER, Elazer R. EDELMAN
  • Patent number: 10517883
    Abstract: A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intra-cellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: December 31, 2019
    Assignee: ZULI HOLDINGS LTD.
    Inventors: Haim D. Danenberg, Gershon Golomb, Elazer R. Edelman
  • Publication number: 20190175372
    Abstract: An electronic intravascular device is placed in tight contact with vessel walls and is used for electrical stimulation and/or electrical recording of the vessel wall and surrounding target tissue. The electrodes may operate via connectors interfacing them to external hardware or may incorporate electronics to allow wireless power, information transfer, and control. The device includes an internal skeleton, a flexible substrate attached to the exterior of the skeleton, at least one pair of electrodes located on the substrate, and power and control circuitry connected to the electrodes. The power and control circuitry may include connectors for direct powering of the electrodes or circuit elements for wireless powering of the device by RF-based, optical-based, ultrasound-based, piezoelectric, or vibrational energy harvesting methods.
    Type: Application
    Filed: July 23, 2018
    Publication date: June 13, 2019
    Applicants: Massachusetts Institute of Technology, Washington University
    Inventors: Edward Stuart Boyden, Giovanni Talei Franzesi, Christian Wentz, Nir Grossman, Elazer R. Edelman, Colin Derdeyn, Eric Leuthardt
  • Patent number: 10318707
    Abstract: Apparatus, systems, and methods are provided for assessing clot activity in blood under various conditions in vitro. The apparatus includes a plurality of test receptacles that receive the blood, at least one flow generating mechanism in communication with the test receptacles, and a clot detector configured to analyze an amount of clot formation that occurs within the blood in each receptacle. Blood contacting surfaces of a first subset of the test receptacles are coated with a first surface substrate and blood contacting surfaces of a second subset of the test receptacles are coated with a different second surface substrate. The flow generating mechanism is configured to generate a first blood flow rate through a third subset of the test receptacles and to generate a different second blood flow rate through a fourth subset of the test receptacles.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Kumaran Kolandaivelu, Elazer R. Edelman
  • Publication number: 20190142953
    Abstract: Abstract of the Disclosure Provided herein are compositions that include a dendrimer to which a drug and a binding peptide are conjugated. The binding peptide may be configured to bind to a receptor that is overexpressed by a diseased cell, such as a cancer cell. The compositions may include a hydrogel in which the dendrimer-drug conjugate is dispersed. Methods of drug delivery and kits also are provided.
    Type: Application
    Filed: May 10, 2017
    Publication date: May 16, 2019
    Inventors: Elazer R. Edelman, Natalie Artzi, Nuria Oliva
  • Publication number: 20190117678
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 25, 2019
    Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG
  • Patent number: 10213446
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 26, 2019
    Assignee: BIOrest Ltd.
    Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
  • Patent number: 10022222
    Abstract: The present embodiments relate to systems and methods for treating lumenal valves. Particularly, and in accordance with one aspect, the present disclosure is directed to methods and systems for partial or complete replacement of lumenal valves. An exemplary catheter in accordance with the disclosure includes an elongate body having a proximal end and a distal end, and a retractable sheath mounted on the elongate body proximate the distal end. The sheath and elongate body cooperating to define a first annularly-shaped compartment between the body and sheath. The catheter further includes a valve prosthesis mounted in the compartment, the prosthesis having proximal and distal ends connected to a means for deploying the valve prosthesis from the catheter.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: July 17, 2018
    Inventors: Adam Groothuis, Adrian Ebner, Peter Markham, Elazer R. Edelman
  • Publication number: 20180193518
    Abstract: Methods, compositions, kits, and drug delivery devices are provided for treating, adhering, or sealing biological tissues. The methods include combining a first solution that includes an oligomer/polymer component and a second solution that includes a dendrimer component, and at least one of the oligomer/polymer component and dendrimer component includes at least one substituent that is capable of photoreversible dimerization. The reversible dimerization of the substituent may allow for the reversible dimerization and/or polymerization of one or more components. The substituent that is capable of photoreversible dimerization may be active by the application of light, such as UV light.
    Type: Application
    Filed: June 23, 2016
    Publication date: July 12, 2018
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes, Yi Zhang
  • Publication number: 20180161362
    Abstract: Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes
  • Publication number: 20180055860
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Application
    Filed: October 24, 2017
    Publication date: March 1, 2018
    Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG
  • Patent number: 9877984
    Abstract: Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 30, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes
  • Publication number: 20170367705
    Abstract: The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a microcrystalline structure and techniques for increasing vascular permeability for drug application and retention. Particular aspects may be directed to a medical device including a balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes microcrystals in a haystack orientation having random and a substantial absence of uniformity in placement and/or angle on the outer surface of the balloon.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 28, 2017
    Inventors: Steven M. Alston, Elazer R. Edelman, Peter Heicksen, Theresa A. Holland, Peter M. Markham, Peter D. Traylor, Abraham Tzafriri, Brett G. Zani